Patients choose: transplant or Non-Transplant for rare bone marrow cancer?

NCT ID NCT04217356

Ongoing Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study looks at two treatment options for people with a high-risk form of myelofibrosis, a rare bone marrow cancer. Participants choose whether they want a stem cell transplant or the best non-transplant treatments available. Researchers then track survival and quality of life to see which approach works better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE MARROW CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bone marrow cancer bone marrow neoplasm myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BONE MARROW CANCER HIGH-RISK CANCER MYELOFIBROSIS

Contacts and locations

Locations

Cross Cancer Institute

Edmonton, Alberta, T6G2G3, Canada
Nova Scotia Health Authority

Halifax, Nova Scotia, B3H2Y9, Canada
Princess Margaret Cancer Centre

Toronto, Ontario, M5G2M9, Canada
St. Paul's Hospital

Vancouver, British Columbia, V6E1M7, Canada
Tom Baker Cancer Centre

Calgary, Alberta, T2N4N2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.